

Impression Executes Exclusive CBD Product Supply Agreement with AXIM Biotechnologies for Periodontitis – First Clinical Trial Imminent

Highlights:

- Impression enters its first exclusive license and supply agreement with AXIM Biotechnologies Inc, a company at the forefront of cannabinoid research
- The license and supply agreement is a precursor to the imminent commencement of the clinical trial for CBD mouthwash and toothpaste for Periodontitis to be undertaken by Swinburne University of Technology
- Approximately 20% of the Australian population (5M people), and almost 40% of Australians aged 55 years or over, have moderate-to-severe periodontitis, otherwise known as Gum Disease
- The new binding agreement also incorporates a longer dated 3-year first-right-of-refusal over all current and future AXIM products
- The agreement may serve as a template for additional products from AXIM to be introduced into the Australian and New Zealand markets by Impression.

Impression Healthcare Limited ('Impression', 'IHL' or the 'Company') is pleased to announce that it has executed an exclusive supply agreement with AXIM Biotechnologies Inc. ('AXIM') for the supply of toothpaste and mouthwash ('Products') containing cannabidiol ('CBD') for the treatment of Periodontitis (Gum Disease).

AXIM will supply the first batch of toothpaste and mouthwash and associated placebo units required for a randomised control clinical trial of up to 40 participants. Following the completion of a successful clinical trial and special access scheme ('SAS') sales authorisation, Impression may exclusively supply the Products on a commercial basis within Australia, and then New Zealand, to any person in accordance with the rules of the SAS, as outlined by the Therapeutic Goods Administration.

Approvals under the SAS have been growing rapidly month-on-month, due to increasing awareness of the benefits of cannabis medicines in the healthcare community. Distribution of the Products is envisaged to be via the Cannvalate network and Impression's own Preferred Practitioner Network of dentists, to which it already distributes oral device products on a B2B basis. Importantly, Dentists are entitled to prescribe their patients medicinal cannabis products under the rules of the SAS.

Impression will immediately commence the process to import the initial batch of Products as soon as practicable in preparation for the clinical trial that will be conducted under the leadership of a team at Swinburne University of Technology. IHL expects that the protocol for the clinical trial will be completed soon and will update the market as to when the trial formally commences.

The immediate financial impact of this transaction to IHL is minimal. As announced on the 21st March 2019 ("Major Distribution Agreement") the cost to IHL of conducting the trial is capped at \$80,000 with the rest of the costs being funded by Cannvalate and Swinburne University of Technology. It would be premature to

forecast any revenue impact until such time as successful trials have been completed at which point Impression will seek supply through the SAS as mentioned above.

AXIM Biotechnologies Incorporated

The new binding agreement for the license and supply of CBD-based toothpaste and mouthwash also incorporates a first-right-of-refusal over all AXIM's current and future products for a period of 3 years, further enhancing the collaboration between AXIM and Impression. The agreement may also serve as a template for additional products from AXIM to be introduced into the Australian and New Zealand markets by Impression.

Headquartered in New York, NY, AXIM is focused on research, development and production of pharmaceutical, nutraceutical, cosmetic and oral health products incorporating cannabinoids. AXIM has established a full chain of production, including extraction, purification, conversion and microencapsulation. It possesses its own proprietary formulations over a range of unique products as a first mover in the medical cannabinoid field.

Impression Healthcare CEO, Mr Joel Latham said; "We're delighted to have cemented our collaboration with AXIM with our first binding agreement over a cannabinoid product. It paves the way for our first clinical trial, to be managed and operated by the Swinburne University of Technology and Cannvalate.

This is the first of four clinical trials to be undertaken this year for a range of products and indications. The trials and subsequent commercial sales represent an exciting new potential avenue for the company to generate sales in one of the fastest growing emerging sectors in the World".

ENDS

About Impression Healthcare Limited (ASX: IHL)

Impression Healthcare Limited is an innovative healthcare company that sells customised oral devices both direct-to-the-consumer and via the Company's growing B2B preferred practitioner network of dentists. With its own laboratory in Victoria, Australia, Impression offers best-in-class teeth-protection and helps its customers to combat bruxism, snoring, mild-to-moderate sleep apnoea and teeth discolouration with custom-fitted oral devices.

Impression has broadened its commitment to disruption in the healthcare sector by progressing multiple opportunities in the field of medicinal cannabis. IHL has its licenses in place to import, export and distribute cannabis products. In March of 2019, Impression executed a binding collaboration with Cannvalate and Swinburne University of Technology to undertake four medicinal cannabis clinical trials. Cannvalate is Australia's largest distributor of medicinal cannabis products.

IHL also has a collaboration agreement with leading US Cannabinoid therapeutics Company, AXIM Biotechnologies Incorporated; a license agreement with Resolution Chemicals for the production and distribution of Dronabinol in the USA, Canada, Australia and New Zealand; and also intends to distribute medicinal cannabis oils through the Cannvalate network of cannabis medicine prescribers throughout Australia.

Investors: investors@impression.healthcare

Website: www.impression.healthcare